webinar register page

Webinar banner
Cardiol Therapeutics Investors Roundtable
Cardiol Therapeutics is a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease

The Company brings together a wealth of research and development experience, advanced manufacturing capabilities, and a Management team, Board of Directors, and Scientific and Business Advisory Boards comprising business and thought leaders with extensive industry experience and expertise in commercializing proprietary drugs.

Cardiol has received clearance from the U.S. FDA for its Investigational New Drug (IND) application that is being investigated in a Phase II/III outcomes study (the LANCER Trial). A double-blind, placebo-controlled clinical trial investigating the efficacy and safety of its lead clinical product, CardiolRx™, as a cardioprotective therapy to reduce mortality and major cardiovascular events in patients hospitalized with COVID-19 who have a prior history of, or risk factors for cardiovascular disease (CVD), and to investigate the influence CardiolRx has on key markers of inflammatory heart disease. CardiolRx™ is an ultra-pure, high concentration cannabidiol oral formulation that is pharmaceutically produced and manufactured under cGMP.

Cardiol has also received clearance from the FDA for its application for a Phase II international trial that will investigate the anti-inflammatory and anti-fibrotic properties of CardiolRx in patients with acute myocarditis, which remains a leading cause of sudden cardiac death in people under 35 years of age. In addition, Cardiol is developing a subcutaneous formulation of CardiolRx and other anti-inflammatory therapies for the treatment of chronic heart failure – a leading cause of death and hospitalization in North America, with associated annual healthcare costs in the U.S. alone exceeding $30 billion.

15:00 CET
09:00 EST
14:00 UTC
Webinar is over, you cannot register now. If you have any questions, please contact Webinar host: IIF.